Search results for "cholangiocarcinoma"

showing 10 items of 69 documents

Visceral infiltration of intrahepatic cholangiocarcinoma is most prognostic after curative resection - Retrospective cohort study of 102 consecutive …

2018

Intrahepatic cholangiocarcinoma (ICC) is a rare malignancy, and therefore large unicenter series on the surgical outcome are rare in the literature, and prognostic factors for overall survival in the literature vary widely.All patients who underwent surgery for ICC were prospectively recorded. The type of resection, operative details, histological results, morbidity, mortality, overall and recurrence-free survivals as well as prognostic factors were assessed. Prognostic factors were examined by univariate and multivariate analyses. P-values0.05 were considered significant.Between January 2008 and December 2015, 102 patients underwent a resection with curative intent and were included in thi…

AdultMaleCurative resectionmedicine.medical_specialtyMultivariate analysis030230 surgeryMalignancySingle CenterDisease-Free SurvivalCholangiocarcinoma03 medical and health sciences0302 clinical medicinemedicineHepatectomyHumansNeoplasm InvasivenessIntrahepatic CholangiocarcinomaAgedRetrospective StudiesAged 80 and overAnalysis of VarianceUnivariate analysisbusiness.industryRetrospective cohort studyGeneral MedicineMiddle AgedPrognosismedicine.diseaseSurgeryVisceraBile Ducts IntrahepaticTreatment OutcomeBile Duct Neoplasms030220 oncology & carcinogenesisFemaleSurgerybusinessInfiltration (medical)International Journal of Surgery
researchProduct

Characterization of hypoechoic focal hepatic lesions in patients with fatty liver: diagnostic performance and confidence of contrast-enhanced ultraso…

2007

The objective of this study was to assess the diagnostic performance of contrast-enhanced ultrasound (CEUS) to characterize hypoechoic focal hepatic lesions (HFHL) in fatty liver (FL). A study group of 105 patients with FL and 105 HFHLs (52 malignant and 53 benign) underwent CEUS after SonoVue administration. Two blinded readers independently reviewed baseline ultrasound (US) and CEUS scans and classified each lesion as malignant or benign on a five-point scale of confidence, and recorded whether further imaging work-up was needed. Sensitivity, specificity, areas under the receiver operating characteristic (ROC) curve (A (z)), and interobserver agreement were calculated. We observed that th…

AdultMalemedicine.medical_specialtyAdenomaSulfur HexafluorideContrast MediaSensitivity and SpecificityAdenoma Liver CellCholangiocarcinomaFocal Hepatic LesionsFatty LiverContrast-enhanced UltrasoundHumansMedicinecontrast-enhanced ultrasoundfatty liverfocal hepatic lesionsRadiology Nuclear Medicine and imagingProspective StudiesProspective cohort studyPhospholipidsAgedUltrasonographyNeuroradiologyAged 80 and overObserver VariationHyperplasiamedicine.diagnostic_testReceiver operating characteristicbusiness.industryLiver NeoplasmsUltrasoundFatty liverCONTRAST-ENHANCED ULTRASOUNDFATTY LIVERFOCAL HEPATIC LESIONInterventional radiologyGeneral MedicineMiddle Agedmedicine.diseaseFatty LiverLiverROC CurveArea Under CurveFemaleRadiologyHemangiomabusinessContrast-enhanced ultrasoundEuropean Radiology
researchProduct

Hepatocellular carcinoma (HCC) vs. non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018

2019

PURPOSE: The Liver Imaging Reporting and Data System (LI-RADS) was created to standardize the diagnostic criteria for hepatocellular carcinoma (HCC), and has undergone multiple revisions including a recent update in 2018 (v2018). The primary aim of this study was to determine the diagnostic performance and interrater reliability (IRR) of LI-RADS v2018 for distinguishing HCC from non-HCC primary hepatic malignancy in patients ‘at-risk’ for HCC. A secondary aim was to assess the impact of changes introduced in the v2018 diagnostic algorithm. METHODS: This retrospective study combined a 10-year experience of pathologically-proven primary liver malignancies from two large liver transplant cente…

AdultMalemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularUrologyMalignancySensitivity and SpecificityArticle030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineInternal medicineImage Interpretation Computer-AssistedmedicineHumansRadiology Nuclear Medicine and imagingIn patientLiver imagingAgedRetrospective StudiesAged 80 and overCirrhosiRadiological and Ultrasound Technologybusiness.industryLiver NeoplasmsGastroenterologyReproducibility of ResultsRetrospective cohort studyHepatologyMiddle Agedmedicine.diseaseMagnetic Resonance ImagingInterrater reliabilitydigestive system diseasesCombined hepatocellular-cholangiocarcinoma (cHCC-CCA)030220 oncology & carcinogenesisHepatocellular carcinomaCohortLI-RADSFemaleRadiologybusinessTomography X-Ray ComputedIntrahepatic cholangiocarcinoma (iCCA)Algorithms
researchProduct

Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicen…

2019

Abstract Background and Aims Primary sclerosing cholangitis [PSC] is usually associated with inflammatory bowel disease [IBD]. An increased risk of malignancies, mainly colorectal cancer [CRC] and cholangiocarcinoma [CCA], has been reported in PSC-IBD patients. Our aim was to determine the clinical characteristics and management of PSC in IBD patients, and the factors associated with malignancies. Methods PSC-IBD patients were identified from the Spanish ENEIDA registry of GETECCU. Additional data were collected using the AEG-REDCap electronic data capture tool. Results In total, 277 PSC-IBD patients were included, with an incidence rate of 61 PSC cases per 100 000 IBD patient-years, 69.7% …

AdultMalemedicine.medical_specialtyendocrine system diseasesColorectal cancerCholangitis SclerosingRisk AssessmentGastroenterologyInflammatory bowel diseasedigestive systemPrimary sclerosing cholangitisCholangiocarcinomaBile Ducts ExtrahepaticRisk FactorsInterquartile rangeinflammatory bowel diseaseInternal medicineHumansMedicineRetrospective Studiesbusiness.industryPrimary sclerosing cholangitisHazard ratiodigestive oral and skin physiologyGastroenterologyRetrospective cohort studyGeneral MedicineOdds ratioMiddle AgedInflammatory Bowel Diseasesmedicine.diseaseSurvival AnalysisUlcerative colitisdigestive system diseasesPatient Care ManagementBile Ducts IntrahepaticSpainFemalePrimary sclerosing cholangitis inflammatory bowel disease malignancyColorectal Neoplasmsbusinessmalignancy
researchProduct

Fully robotic left hepatectomy for malignant tumor: technique and initial results

2018

Robotic liver surgery has been considered as a unique opportunity to overcome the traditional limitations of laparoscopy; thus, it can potentially extend the indications of minimally invasive liver surgery. From April 2015 to May 2017, 35 patients underwent fully robotic left hepatectomy. The mean operative time was 315 min (200-445 min) and the mean estimated blood loss was 245 ml (125-628 ml). Pringle maneuver was required in six cases. Cancer was the indication for surgery in all patients (14 liver metastases, 18 hepatocellular carcinomas and 3 cholangiocarcinomas). There were one to four lesions in a patient and the mean lesion size was 39.2 mm (15-85 mm). The average length of hospital…

Adultmedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentOperative TimeBlood Loss Surgical030230 surgeryCholangiocarcinomaLesion03 medical and health sciences0302 clinical medicineRobotic Surgical ProceduresBlood lossMinimally invasive surgerymedicineHepatectomyHumansRobotic left hepatectomyLaparoscopyAgedLiver resectionmedicine.diagnostic_testbusiness.industryMortality rateLiver NeoplasmsMargins of ExcisionCancerPerioperativeLength of StayMiddle Agedmedicine.diseaseRobotic liver resectionSurgerySettore MED/18 - Chirurgia GeneraleTreatment OutcomeLiver030220 oncology & carcinogenesisOperative timeFemaleSurgeryHepatectomymedicine.symptombusinessUpdates in Surgery
researchProduct

Correlation of Tumor Density Changes on CT with 18FDG PET Activity for Response Assessment in Advance Bile Duct Cancer

2009

Bile duct cancer CholangiocarcinomaSettore MED/36 - Diagnostica Per Immagini E Radioterapia
researchProduct

Liver Transplantation for Unresectable Intrahepatic Cholangiocarcinoma: The Role of Sequencing Genetic Profiling

2021

Simple Summary Intrahepatic cholangiocarcinoma is a rare disease with increasing incidence and mortality still characterized by an insufficient clinical outcome. Growing attention has recently surrounded this disease, and liver transplantation has emerged as a novel curative treatment for cholangiocarcinoma, along with a better understanding of genetic alterations potentially capable of driving tumorigenesis. The aim of this paper is to present a clinical description of our case series of patients affected by intrahepatic cholangiocarcinoma and by mixed forms of hepatocellular and cholangiocellular carcinoma, together with a genomic profiling of mutations occurring in a panel of genes relev…

Cancer ResearchLiver tumorliver transplantationbusiness.industrymedicine.medical_treatmentWnt signaling pathwayCancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensLiver transplantationmedicine.diseasemedicine.disease_causeArticlenext-generation sequencing.Oncologyintrahepatic cholangiocarcinomamedicineCancer researchnext-generation sequencingKRASCarcinogenesisbusinessPI3K/AKT/mTOR pathwayIntrahepatic CholangiocarcinomaRC254-282intrahepatic cholangiocarcinoma; liver transplantation; next-generation sequencingCancers
researchProduct

FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements.

2019

TPS468 Background: Intrahepatic cholangiocarcinoma (iCCA) is a cancer arising from the intrahepatic bile duct. Standard treatment of unresectable, recurrent, or metastatic iCCA is with cytotoxic chemotherapy. FGFR2 gene fusions have been identified as oncogenic drivers in 10–20% of iCCA tumors, but no targeted agents have been established to date. TAS-120 is an investigational irreversible FGFR1–4 inhibitor in development as a once-daily oral treatment for iCCA. Based on initial studies in multiple tumor types expressing FGFR abnormalities, iCCA was identified as a tumor type with potential susceptibility to FGFR inhibition and high unmet need. A phase I portion of the trial with an iCCA e…

Cancer Researchbusiness.industryStandard treatmentIntrahepatic bile ductsCancermedicine.disease03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesisCancer researchmedicineCytotoxic T cellIn patientbusinessGeneIntrahepatic Cholangiocarcinoma030215 immunologyJournal of Clinical Oncology
researchProduct

Systematic review with radiomics quality score of cholangiocarcinoma: an EuSoMII Radiomics Auditing Group Initiative

2023

Abstract Objectives To systematically review current research applications of radiomics in patients with cholangiocarcinoma and to assess the quality of CT and MRI radiomics studies. Methods A systematic search was conducted on PubMed/Medline, Web of Science, and Scopus databases to identify original studies assessing radiomics of cholangiocarcinoma on CT and/or MRI. Three readers with different experience levels independently assessed quality of the studies using the radiomics quality score (RQS). Subgroup analyses were performed according to journal type, year of publication, quartile and impact factor (from the Journal Citation Report database), type of cholangiocarcinoma, imaging modali…

CholangiocarcinomaCholangiocarcinoma Systematic review Quality improvement LiverLiverSystematic reviewRadiology Nuclear Medicine and imagingCholangiocarcinoma; Liver; Quality improvement; Systematic reviewQuality improvement
researchProduct

The Co‐mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion‐Driven Cholangiocarcinoma

2021

Background and aims Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer and a highly lethal malignancy. Chemotherapeutic options are limited, but a considerable subset of patients harbors genetic lesions for which targeted agents exist. Fibroblast growth factor receptor 2 (FGFR2) fusions belong to the most frequent and therapeutically relevant alterations in ICC, and the first FGFR inhibitor was recently approved for the treatment of patients with progressed, fusion-positive ICC. Response rates of up to 35% indicate that FGFR-targeted therapies are beneficial in many but not all patients. Thus far, no established biomarkers exist that predict resistance or r…

Fetal Proteins0301 basic medicineAntimetabolites AntineoplasticCombination therapymedicine.medical_treatmentFGFR InhibitionVesicular Transport ProteinsCyclic AMP Response Element-Binding Protein Amedicine.disease_causeDeoxycytidineMalignant transformationTargeted therapyCholangiocarcinomaProto-Oncogene Proteins p21(ras)Mice03 medical and health sciencesLiver Neoplasms Experimental0302 clinical medicineAntigens NeoplasmmedicineAnimalsReceptor Fibroblast Growth Factor Type 2Protein Kinase InhibitorsCell ProliferationHepatologyOncogenebusiness.industryFibroblast growth factor receptor 2AdenosylhomocysteinasePhenylurea CompoundsGemcitabineBile Ducts IntrahepaticCell Transformation NeoplasticPyrimidines030104 developmental biologyBile Duct NeoplasmsFibroblast growth factor receptorMutationCancer research030211 gastroenterology & hepatologyKRASGene FusionbusinessCo-Repressor ProteinsMicrotubule-Associated ProteinsHepatology
researchProduct